Richard E. Gammans
President chez Pamlico BioPharma, Inc.
Profil
Richard E.
Gammans currently works at Otologic Pharmaceutics, Inc., as President & Chief Operating Officer and Pamlico BioPharma, Inc., as President & Chief Operating Officer.
Dr. Gammans also formerly worked at Bristol Myers Squibb Co., as Global Project Director & Senior Scientist, Indevus Pharmaceuticals, Inc., as Senior Vice President-Clinical Research from 1994 to 2000, Incara Pharmaceuticals Corp., as Executive Vice President-Research & Development from 2000 to 2004, and MediciNova, Inc., as Chief Development Officer from 2004 to 2009.
Dr. Gammans received his graduate degree from Purdue University and graduate degree and doctorate degree from the University of Georgia.
Postes actifs de Richard E. Gammans
| Sociétés | Poste | Début |
|---|---|---|
Pamlico BioPharma, Inc.
 Pamlico BioPharma, Inc. BiotechnologyHealth Technology Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK. | President | - |
Otologic Pharmaceutics, Inc.
 Otologic Pharmaceutics, Inc. Pharmaceuticals: MajorHealth Technology Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK. | President | - |
Anciens postes connus de Richard E. Gammans
| Sociétés | Poste | Fin |
|---|---|---|
| MEDICINOVA, INC. | Corporate Officer/Principal | 12/06/2009 |
| Incara Pharmaceuticals Corp. | Directeur Technique/Scientifique/R&D | 09/08/2004 |
Indevus Pharmaceuticals, Inc.
 Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Directeur Technique/Scientifique/R&D | 01/05/2000 |
| BRISTOL-MYERS SQUIBB COMPANY | Corporate Officer/Principal | - |
Formation de Richard E. Gammans
| Purdue University | Graduate Degree |
| University of Georgia | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| BRISTOL-MYERS SQUIBB COMPANY | Health Technology |
| MEDICINOVA, INC. | Health Technology |
| Entreprise privées | 4 |
|---|---|
Indevus Pharmaceuticals, Inc.
Indevus Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Indevus Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the acquisition, development and commercialization of products in the fields of urology, gynecology and infectious diseases. The company markets it's product SANCTURA for the treatment of overactive bladder and has compounds in clinical development including SANCTURA XR, NEBIDO, PRO 2000, IP 751, Pagoclone and Aminocandin. It focuses on the clinical development, regulatory review and commercialization of biopharmaceutical products. Indevus Pharmaceuticals was founded in 1988 and is headquartered in Lexington, MA. | Health Technology |
| Incara Pharmaceuticals Corp. | Health Technology |
Otologic Pharmaceutics, Inc.
Otologic Pharmaceutics, Inc. Pharmaceuticals: MajorHealth Technology Otologic Pharmaceutics, Inc. develops treatment for acute hearing loss. Its product HPN1010 is an oral medication to treat acute hearing loss to reduce the development of permanent hearing disorders. The company was founded by Richard Kopke, Robert A. Floyd and Dave karlman and is headquartered in Oklahoma City, OK. | Health Technology |
Pamlico BioPharma, Inc.
Pamlico BioPharma, Inc. BiotechnologyHealth Technology Pamlico BioPharma, Inc. provides antibody therapeutics services. It develops fully-human monoclonal antibody (hmAb) therapeutics for the rapid diagnosis and treatment of infectious diseases and cancer. The firms lead program is focused on severe pneumonia caused by streptococcus pneumoniae (SPN), and is in preclinical IND-directed activities for a mAb cocktail and a companion point-of-care (POC) diagnostic against three serotypes that account for over 40% of SPN infections. The company was founded on 18 December, 2014 and is headquartered in Oklahoma, OK. | Health Technology |
